Exmoor Pharma Concepts Limited

Biomanufacturing of gene therapies is a complex process, hampered by variability in yield, quality, and scalability of manufacturing platforms. Fundamentally, manufacturing of viral vectors is a biologically based process and as such, understanding and optimizing biological drivers of yield and quality represents a key strategy to maximizing biomanufactur...

There is a market need for tertiary processing of cell therapies at the Point of Care (PoC) in order to be able to extend the shelf life of valuable products, remove uncertainty in the final processing and increase patient safety. CPrep is a closed, automated PoC device consisting of a Processor and a single use Disposable which meets this need. It takes ...

This project will establish a world-class consortium to innovatively address a critical step in administering cellular products for the cell therapy industry (CTI) – a robust validated platform technology to enable post-manufacturing process steps to be carried out at the point of care (PoC). This Closed-point-of-care-Preparation device will increase pati...

Cell Medica, develops, manufactures and provides cellular immunotherapy products for the treatment of infectious disease and cancer. Cell Medica Ltd collaborated with eXmoor Pharma Concepts Ltd and University College London (UCL) on this project, with the aim of the development of a scaled-up manufacturing process for production of virus specific T cell t...